Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) represents the dominant driver behind hepatocellular carcinoma (HCC), the predominant form of liver cancer and a leading cause of cancer-related mortality worldwide. Although the correlation between chronic viral hepatitis and HCC is well-established, the precise mechanisms by which these persistent infections evolve into malignant tumors remain elusive. This knowledge gap is partially attributable to the species-specific nature of hepatitis viruses, which has impaired the creation of animal models that faithfully mimic the disease timeline seen in humans.

Previous attempts to circumvent this obstacle have involved techniques such as viral adaptation, genetic humanization of murine liver cells, or transplantation of human liver tissues into mice. While these approaches have provided valuable insights, none have managed to replicate the natural course of chronic hepatitis advancing sequentially to scarring and ultimately liver cancer. The absence of an immunocompetent animal model that spontaneously develops HCC over time has limited preclinical evaluation of therapies and fundamental investigation into viral-host interactions during disease progression.

In a pioneering effort, researchers harnessed an engineered variant of Norway rat hepacivirus (NrHV), a viral relative of HCV known to infect the livers of wild rats in New York City, as a surrogate agent to establish persistent infection in standard laboratory mice. By transiently suppressing the mice’s immune systems at the onset, they allowed viral establishment before immune recovery. Over an 18-month observation period—analogous to middle age in humans—the team meticulously tracked disease progression, unveiling an impressive replication of human chronic hepatitis pathophysiology, culminating in spontaneous liver tumor formation.

The infected mice developed hallmark immune cell infiltrates and sustained liver inflammation mirroring human HCV-induced hepatitis. Fibrosis accumulated progressively over months, as evidenced by histological analyses, culminating in malignancy in a large majority of animals. Remarkably, by 18 months post inoculation, 67% of infected mice exhibited hepatocellular carcinoma, in stark contrast to merely 4% of control mice. Tumors bore striking histological resemblance to those found in human patients afflicted with HCV-related HCC, validating the model’s clinical relevance.

Moreover, the model captured sex-related disparities observed in human liver cancer. Male mice had more than twice the incidence of HCC compared to females, echoing epidemiological data demonstrating higher susceptibility among men. Intriguingly, a subset of mice that spontaneously cleared the virus still developed liver tumors, reflecting persistent oncogenic risk reported in hepatitis C patients even after viral eradication by direct-acting antivirals. This aspect offers a unique opportunity to explore residual carcinogenesis mechanisms beyond viral persistence.

This viral hepatitis mouse model transcends prior limitations by incorporating an intact immune system, enabling interrogation of complex immune-viral crosstalk during tumorigenesis. Understanding the relative contributions of viral oncogenic factors and immune-mediated inflammation to HCC development becomes feasible with this system. It provides a vital platform to dissect immune evasion strategies, chronic inflammation’s role, and microenvironmental changes facilitating malignant transformation.

Clinically, the model paves the way to rigorously evaluate existing and novel immune-based therapies for liver cancer within a relevant physiological context. Investigators can now investigate why therapies such as immune checkpoint inhibitors display variable efficacy among patients. Moreover, it offers a testing ground for emerging antiviral and anticancer treatments, optimizing therapeutic regimens prior to clinical translation. Early-stage biomarker discovery efforts aimed at identifying indicators predictive of HCC onset also stand to benefit, potentially enabling earlier diagnosis and intervention in human patients.

The innovative work spearheaded by Charles M. Rice and Mariana Nogueira Batista at The Rockefeller University epitomizes scientific advancement by effectively reproducing the complex natural history of hepatitis progressing to liver cancer in an accessible and reproducible animal model. This leap forward will undoubtedly accelerate research into viral hepatitis, liver fibrosis, and hepatocellular carcinoma, ultimately aiding the development of targeted therapies to alleviate a major global health burden. As the model continues to be employed for mechanistic studies and preclinical trials, hope grows for improved patient outcomes through enhanced understanding and novel treatment possibilities.

This new animal model stands as a testament to the power of combining virology, immunology, and cancer biology to solve longstanding challenges. By faithfully mimicking the human disease continuum, it opens unforeseen avenues for scientific inquiry and therapeutic innovation, moving us closer to conquering one of the deadliest cancers worldwide.

Subject of Research: Development of a chronic viral hepatitis mouse model that progresses to hepatocellular carcinoma analogous to hepatitis C virus infection in humans.

Article Title: (Not explicitly stated in content)

News Publication Date: (Not provided)

Web References:
http://dx.doi.org/10.1016/j.jhep.2026.02.020

References: Journal of Hepatology

Image Credits: Laboratory of Virology and Infectious Disease at The Rockefeller University

Keywords: Hepatitis C, Liver cancer, Hepatocellular carcinoma, Viral hepatitis, Norway rat hepacivirus, Chronic infection, Immune system, Liver fibrosis, Animal model, Immunology, Cancer biology, Preclinical trials.

Liver cancer, particularly HCC, often emerges against a backdrop of chronic HBV infection and subsequent liver damage, including cirrhosis. Despite advances in medical imaging and serum biomarkers, catching HCC at an early, treatable stage has proved elusive. The promise of extracellular vesicles as carriers of disease-specific molecular signatures opens new frontiers. These nanometer-sized vesicles, secreted by cells into bodily fluids, encapsulate a rich cargo of RNAs, proteins, and lipids reflective of their cellular origin, thus serving as a “liquid biopsy” without the invasiveness of traditional tissue sampling.

In this comprehensive study, serum EVs were isolated from a cohort consisting of healthy controls, chronic hepatitis B (CHB) patients, liver cirrhosis patients, hepatocellular adenoma patients, and those diagnosed with HCC. The use of ultracentrifugation ensured high-purity vesicle isolation, while transmission electron microscopy, nanoparticle tracking analysis, and Western blotting confirmed the isolated EVs’ identity and purity. This rigorous validation underpins the credibility of subsequent molecular analyses.

High-throughput transcriptome sequencing was employed to profile RNA content within EVs from each clinical group, enabling systematic comparisons of lncRNA expression associated with disease progression. The study identified an array of 133 lncRNAs demonstrating significant differential expression specifically in the HCC group, underscoring their potential as biomarkers uniquely linked to malignant transformation in HBV-related liver disease.

The analytical framework extended beyond mere identification. Through multi-step screening and time-series analysis, the researchers pinpointed 10 core lncRNAs closely correlated with HCC progression. These lncRNAs exhibit dynamic expression changes aligning with clinical stages, suggesting their active involvement in the tumorigenic process rather than passive association. Such specificity is key to their potential deployment in diagnostic applications.

Diving deeper into molecular mechanisms, the authors constructed a complex lncRNA-miRNA-mRNA regulatory network encompassing 62 nodes and 68 interactions. This network sheds light on the layered post-transcriptional regulation and cross-talk among diverse RNA species. It highlights how lncRNAs may act as competing endogenous RNAs (ceRNAs), modulating miRNA availability and downstream mRNA expression, thereby influencing cellular pathways relevant to tumor growth and survival.

Functional enrichment analyses provided compelling hints about the biological processes modulated by these lncRNAs. The implicated pathways include critical aspects of cell proliferation regulation, transmembrane ion transport, cytosolic and plasma membrane localization, protein binding interactions, and vital signaling cascades such as autophagy and the mitogen-activated protein kinase (MAPK) pathway. These findings reveal the multifaceted impact of EV-derived lncRNAs on cellular homeostasis and oncogenic signaling networks.

Protein-protein interaction (PPI) network analysis further distilled the hub genes within this regulatory landscape, identifying 10 key genes including NTRK2 and KCNJ10. These hub genes likely serve as pivotal nodes mediating cross-talk within the signaling circuitry, rendering them potential targets for therapeutic intervention or biomarker validation.

To ensure robustness, the study validated the expression patterns of core lncRNAs and their downstream genes using an independent plasma cohort. The consistency observed across distinct patient populations strengthens the case for these molecules as reproducible biomarkers with clinical diagnostic value, potentially enabling real-time monitoring of disease progression via minimally invasive blood tests.

The implications of these findings are profound. By elucidating a set of HCC-specific lncRNA biomarkers packaged within extracellular vesicles, the study pioneers a paradigm enabling clinicians to leverage liquid biopsy techniques for early detection of liver cancer in high-risk HBV-infected individuals. Such breakthroughs promise to enhance prognosis by facilitating timely therapeutic interventions and personalized treatment strategies.

Moreover, the mechanistic insights into EV lncRNA-mediated regulatory networks enhance our understanding of tumor biology, possibly unveiling novel therapeutic avenues aimed at disrupting pathological signaling cascades in HCC. Targeting these EV-associated lncRNAs or their interacting partners could augment current treatment modalities and improve patient outcomes.

This research underscores the formidable potential of integrating advanced molecular profiling with cutting-edge bioinformatic analyses to decode the complexities of cancer progression. The marriage of transcriptomics, network biology, and clinical validation exemplifies a holistic approach that could be adapted to other malignancies where EV-derived molecules serve as biomarkers and mediators.

As the scientific community continues to grapple with liver cancer’s global toll, discoveries like these mark a critical stepping stone towards mitigating disease burden through early, precise, and non-invasive diagnosis. The promise of EV-derived lncRNAs heralds a new era where liquid biopsies transcend experimental status to become standard clinical tools.

Future research will likely explore how these EV-lncRNA signatures interact with the immune microenvironment, influence metastatic potential, and respond to therapeutic pressures. Longitudinal studies across larger cohorts will also be essential to verify clinical utility and refine biomarker panels for widespread screening initiatives.

In conclusion, this pioneering investigation charts a sophisticated molecular atlas of EV-derived lncRNAs linked to HBV-related HCC progression. It not only illuminates key biological pathways modulated during hepatocarcinogenesis but also lays the groundwork for transformative liquid biopsy-based diagnostic platforms. As such, it offers renewed hope for millions threatened by liver cancer worldwide.

Subject of Research: Characteristics and mechanistic roles of extracellular vesicle-derived long non-coding RNAs during HBV-related hepatocellular carcinoma progression.

Article Title: Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma

Article References:
Ma, Y., Lou, C., liang, J. et al. Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma. BMC Cancer 25, 1768 (2025). https://doi.org/10.1186/s12885-025-15237-y

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15237-y (Published 14 November 2025)